1-tert-butyl 4-ethyl 1H-pyrazole-1,4-dicarboxylate | 405103-00-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-tert-butyl 4-ethyl 1H-pyrazole-1,4-dicarboxylate
• 英文别名: ethyl (1-tert-butyloxycarbonyl)pyrazole-4-carboxylate；ethyl 1-(tert-butoxycarbonyl)pyrazole-4-carboxylate；1-O-tert-butyl 4-O-ethyl pyrazole-1,4-dicarboxylate
• CAS: 405103-00-6
• 化学式: C₁₁H₁₆N₂O₄
• 分子量: 240.259
• InChiKey: OHJCPQXLPDDCRI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  70.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-tert-butyl 4-ethyl 1H-pyrazole-1,4-dicarboxylate 在 二异丁基氢化铝 作用下， 以 四氢呋喃 、 水 、 甲苯 为溶剂， 生成 4-(羟基甲基)-1H-吡唑-1-羧酸叔丁酯
  参考文献：
  名称：

  NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF

  摘要：

  公开号：

  EP1318140B9
• 作为产物：
  描述：

  4-吡唑甲酸乙酯 、 二碳酸二叔丁酯 在 4-二甲氨基吡啶 silica gel 作用下， 以 四氢呋喃 为溶剂， 反应 7.0h， 以to give 1-tert-butyl 4-ethyl 1H-pyrazole-1,4-dicarboxylate (28.9 g)的产率得到1-tert-butyl 4-ethyl 1H-pyrazole-1,4-dicarboxylate
  参考文献：
  名称：

  Optically Active Tetrahydronaphthalene Derivative

  摘要：

  以下式子(I)所代表的化合物，其药理学上可接受的盐、水合物或溶剂化物，不仅显示出C5a受体拮抗活性，而且相对于其外消旋体具有高生物利用度的活性。

  公开号：

  US20080194640A1

文献信息

• [EN] TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE<br/>[FR] INHIBITEURS, À BASE DE TRIAZOLOPYRIDINE, DE LA MYÉLOPEROXYDASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017040449A1

  公开（公告）日：2017-03-09

  The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

  本发明提供了化合物的结构式（I）：其中A如规范中定义，并包括任何此类新化合物的组合物。这些化合物是髓过氧化物酶（MPO）抑制剂和/或嗜酸性粒细胞过氧化物酶（EPX）抑制剂，可用作药物。
• [EN] TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE<br/>[FR] INHIBITEURS DE LA MYÉLOPEROXYDASE À BASE DE TRIAZOLOPYRIDINES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017160632A1

  公开（公告）日：2017-09-21

  The present invention provides compounds of Formula (I). wherein A and Z are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and may be useful for for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

  本发明提供了式（I）的化合物。其中A和Z如规范中所定义，并包括任何这类新化合物的组合物。这些化合物是髓过氧化物酶（MPO）抑制剂，可能对动脉粥样硬化、心力衰竭、慢性阻塞性肺病（COPD）及相关疾病的治疗和/或预防有用。
• Novel amide derivatives and medicinal use thereof
  申请人：NAKAMURA Mitsubaru

  公开号：US20100041656A1

  公开（公告）日：2010-02-18

  The present invention relates to an amide derivative of the formula (1), having a C5a receptor antagonistic action wherein each symbol is as defined in the specification. The above-mentioned amide derivative, an optically active form thereof and a pharmaceutically acceptable salt thereof are promising as an agent for the treatment or prophylaxis of diseases or syndromes caused by inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis and pancreatitis and the like) due to activation of leukocytes caused by ischemia reperfusion, trauma, burn, surgical invasion and the like]. Moreover, they are useful as a therapeutic or prophylactic agent for the infectious diseases caused by bacteria and virus that invade via a C5a receptor.

  本发明涉及一种式（1）的酰胺衍生物，具有C5a受体拮抗作用，其中每个符号如规范中所定义。上述酰胺衍生物及其光学活性形式和药学上可接受的盐被认为是治疗或预防由C5a引起的炎症所致疾病或综合症的药物，例如自身免疫性疾病，如风湿病，系统性红斑狼疮等，败血症，成人呼吸窘迫综合症，慢性阻塞性肺疾病，过敏性疾病，如哮喘等，动脉硬化，心脏梗塞，脑梗塞，牛皮癣，阿尔茨海默病和严重器官损伤（例如，肺炎，肾炎，肝炎，胰腺炎等），由缺血再灌注，创伤，烧伤，手术侵袭等引起的白细胞激活所致。此外，它们还可用作通过C5a受体侵入的细菌和病毒引起的传染病的治疗或预防剂。
• Amide derivatives and medicinal use thereof
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：US07855297B2

  公开（公告）日：2010-12-21

  The present invention relates to an amide derivative of the formula (1), having a C5a receptor antagonistic action wherein each symbol is as defined in the specification. The above-mentioned amide derivative, an optically active form thereof and a pharmaceutically acceptable salt thereof are promising as an agent for the treatment or prophylaxis of diseases or syndromes caused by inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis and pancreatitis and the like) due to activation of leukocytes caused by ischemia reperfusion, trauma, burn, surgical invasion and the like]. Moreover, they are useful as a therapeutic or prophylactic agent for the infectious diseases caused by bacteria and virus that invade via a C5a receptor.

  本发明涉及一种具有C5a受体拮抗作用的公式（1）的酰胺衍生物，其中每个符号如规范中所定义。上述酰胺衍生物及其光学活性形式和药学上可接受的盐作为治疗或预防由C5a引起的炎症引起的疾病或综合征的药物很有前途[例如，自身免疫疾病，如风湿病，系统性红斑狼疮等，败血症，成人呼吸窘迫综合症，慢性阻塞性肺疾病，过敏疾病，如哮喘等，动脉硬化，心肌梗死，脑梗死，牛皮癣，阿尔茨海默病和严重器官损伤（例如，由缺血再灌注，创伤，烧伤，手术入侵等引起的白细胞激活引起的肺炎，肾炎，肝炎和胰腺炎等）]。此外，它们也可用作通过C5a受体侵入的细菌和病毒引起的传染病的治疗或预防药物。
• Malonic acid sulfonamide derivative and pharmaceutical use thereof
  申请人：Yoshida Tomohiro

  公开号：US08461209B2

  公开（公告）日：2013-06-11

  The invention provides a sulfonyl malonamide derivative, or a pharmacologically acceptable salt thereof or a solvate thereof, that has therapeutic and/or preventive effects(s) on various diseases due to its agonist action at AT2 receptor, and is useful as a pharmaceutical agent for the treatment and/or prevention of diseases involving the renin-angiotensin-aldosterone system (RAAS).

  本发明提供了一种磺酰基马隆酰胺衍生物，或其药学上可接受的盐或溶剂，由于其在AT2受体上的激动剂作用，具有对各种疾病的治疗和/或预防作用，并可用作治疗和/或预防涉及肾素-血管紧张素-醛固酮系统（RAAS）疾病的药物。